+
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection

Abstract

Age is the dominant risk factor for infectious diseases, but the mechanisms linking age to infectious disease risk are incompletely understood. Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA, are structural somatic variants indicative of clonal hematopoiesis, and are associated with aberrant leukocyte cell counts, hematological malignancy, and mortality. Here, we show that mCAs predispose to diverse types of infections. We analyzed mCAs from 768,762 individuals without hematological cancer at the time of DNA acquisition across five biobanks. Expanded autosomal mCAs were associated with diverse incident infections (hazard ratio (HR) 1.25; 95% confidence interval (CI) = 1.15–1.36; P = 1.8 × 10−7), including sepsis (HR 2.68; 95% CI = 2.25–3.19; P = 3.1 × 10−28), pneumonia (HR 1.76; 95% CI = 1.53–2.03; P = 2.3 × 10−15), digestive system infections (HR 1.51; 95% CI = 1.32–1.73; P = 2.2 × 10−9) and genitourinary infections (HR 1.25; 95% CI = 1.11–1.41; P = 3.7 × 10−4). A genome-wide association study of expanded mCAs identified 63 loci, which were enriched at transcriptional regulatory sites for immune cells. These results suggest that mCAs are a marker of impaired immunity and confer increased predisposition to infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic diagram of the study flow, and distribution of mCAs with age and sex.
Fig. 2: Associations of mCAs with hematologic traits.
Fig. 3: Association of expanded mCAs with incident infections.
Fig. 4: Association of expanded autosomal mCAs and incident infections, stratified by antecedent cancer history.
Fig. 5: Association of expanded mCAs with COVID-19 severity.
Fig. 6: Inherited risk factors for expanded mCAs: GWAS, TWAS and cell-type enrichment.

Similar content being viewed by others

Data availability

UKB individual-level data are available by request via application (https://www.ukbiobank.ac.uk). The mCA call set was previously returned to the UKB (return 2062) to enable individual-level linkage to approved UKB applications. Individual-level MGBB data are available from https://personalizedmedicine.partners.org/Biobank/Default.aspx, but restrictions apply to the availability of these data, which were used under institutional review board (IRB) approval for the current study, and so are not publicly available. The BBJ genotype data are available from the Japanese Genotype-phenotype Archive (JGA; http://trace.ddbj.nig.ac.jp/jga/index_e.html) under accession code JGAD00000000123. Individual-level linkage of mosaic events can be provided by the BBJ project upon request (https://biobankjp.org/english/index.html). FinnGen data may be accessed through Finnish Biobanks’ FinnBB portal (www.finbb.fi). Individual-level CUB COVID-19 data, including the mCA call set, are available by application from https://www.ps.columbia.edu/research/core-and-shared-facilities/core-facilities-category/columbia-university-biobank, but consent-related restrictions apply to the availability of these data, and data access requires separate IRB approval for the proposed data use. Aggregate data are also available upon reasonable request. Additionally, the full expanded mCA genome-wide association summary statistics have been uploaded onto the LocusZoom website (https://my.locuszoom.org/gwas/525823/). The present article includes all other data generated or analyzed during this study.

Code availability

A standalone software implementation (MoChA) of the algorithm used to call mCAs is available at https://github.com/freeseek/mocha. A pipeline to execute the whole workflow from raw files all the way to final mCA calls is available in WDL format for the Cromwell execution engine as part of MoChA. Code for all other computations is available upon request from the corresponding authors.

References

  1. Gardner, I. D. The effect of aging on susceptibility to infection. Rev. Infect. Dis. 2, 801–810 (1980).

    Article  CAS  PubMed  Google Scholar 

  2. Gavazzi, G. & Krause, K. H. Ageing and infection. Lancet Infect. Dis. 2, 659–666 (2002).

    Article  PubMed  Google Scholar 

  3. Aw, D., Silva, A. B. & Palmer, D. B. Immunosenescence: emerging challenges for an ageing population. Immunology 120, 435–446 (2007).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Franceschi, C., Bonafe, M. & Valensin, S. Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. Vaccine 18, 1717–1720 (2000).

    Article  CAS  PubMed  Google Scholar 

  5. Ongradi, J. & Kovesdi, V. Factors that may impact on immunosenescence: an appraisal. Immun. Ageing 7, 7 (2010).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Panda, A. et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 30, 325–333 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Aoshi, T., Koyama, S., Kobiyama, K., Akira, S. & Ishii, K. J. Innate and adaptive immune responses to viral infection and vaccination. Curr. Opin. Virol. 1, 226–232 (2011).

    Article  CAS  PubMed  Google Scholar 

  8. Holly, M. K., Diaz, K. & Smith, J. G. Defensins in viral infection and pathogenesis. Annu. Rev. Virol. 4, 369–391 (2017).

    Article  CAS  PubMed  Google Scholar 

  9. Pallett, L. J., Schmidt, N. & Schurich, A. T cell metabolism in chronic viral infection. Clin. Exp. Immunol. 197, 143–152 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Terao, C. et al. Chromosomal alterations among age-related haematopoietic clones in Japan. Nature 584, 130–135 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Loh, P.-R., Genovese, G. & McCarroll, S. A. Monogenic and polygenic inheritance become instruments for clonal selection. Nature 584, 136–141 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Loh, P. R. et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 559, 350–355 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lin, S. H. et al. Mosaic chromosome Y loss is associated with alterations in blood cell counts in UK Biobank men. Sci. Rep. 10, 3655 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Forsberg, L. A. et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat. Genet. 46, 624–628 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jacobs, K. B. et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat. Genet. 44, 651–658 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Laurie, C. C. et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat. Genet. 44, 642–650 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Loftfield, E. et al. Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. Sci. Rep. 8, 12316 (2018).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Machiela, M. J. et al. Characterization of large structural genetic mosaicism in human autosomes. Am. J. Hum. Genet. 96, 487–497 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wu, P. et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation. JMIR Med. Inform. 7, e14325 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  20. Thompson, D. J. et al. Genetic predisposition to mosaic Y chromosome loss in blood. Nature 575, 652–657 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Consortium, G. T. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).

    Article  CAS  Google Scholar 

  22. Lu, Q. et al. Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer’s disease. PLoS Genet. 13, e1006933 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124–131 (2020).

    Article  CAS  PubMed  Google Scholar 

  24. Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20, 1472–1478 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wang, L. et al. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 27, 1300–1311 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. de Weerdt, I. et al. Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. Haematologica 101, e461–e464 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Bartik, M. M., Welker, D. & Kay, N. E. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin. Oncol. 25, 27–33 (1998).

    CAS  PubMed  Google Scholar 

  31. Arruga, F. et al. Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int. J. Mol. Sci. 21, 1825 (2020).

    Article  CAS  PubMed Central  Google Scholar 

  32. Zhou, W. et al. Mosaic loss of chromosome Y is associated with common variation near TCL1A. Nat. Genet. 48, 563–568 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015).

    Article  CAS  PubMed  Google Scholar 

  34. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).

    Article  CAS  PubMed  Google Scholar 

  35. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24–37 (2006).

    Article  PubMed  CAS  Google Scholar 

  36. Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463–469 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27, 992–1000 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Cunha, L. L., Perazzio, S. F., Azzi, J., Cravedi, P. & Riella, L. V. Remodeling of the immune response with aging: immunosenescence and its potential Impact on COVID-19 immune response. Front. Immunol. 11, 1748 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Zekavat, S. M. et al. Elevated blood pressure increases pneumonia risk: epidemiological association and Mendelian randomization in the UK Biobank. Med (NY) 2, 137–148 (2021).

    Article  PubMed  Google Scholar 

  41. Tian, C. et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nat. Commun. 8, 599 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Smoller, J. W. et al. An eMERGE clinical center at Partners Personalized Medicine. J. Pers. Med. 6, 5 (2016).

    Article  PubMed Central  Google Scholar 

  44. Nagai, A. et al. Overview of the BioBank Japan project: study design and profile. J. Epidemiol. 27, S2–S8 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  45. Loh, P. R. et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 48, 1443–1448 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Voss, K., Auwera, G. & Gentry, J. Full-stack genomics pipelining with GATK4 + WDL + Cromwell. F1000Research https://doi.org/10.7490/f1000research.1114631.1 (2017).

  47. Townsend, P., Phillimore, P. & Beattie, A. Health and Deprivation. Inequality and the North (Croom Helm, 1987).

  48. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. 47, 1228–1235 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hu, Y. et al. A statistical framework for cross-tissue transcriptome-wide association analysis. Nat. Genet. 51, 568–576 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank C. Whelan, C. Llanwarne, J. Cerrato, K. Vernest and K. Shakir, and many other members of the Terra/Cromwell team, for their help and advice in the development of the MoChA pipeline. The authors also thank P. Danecek for implementing critical features needed in BCFtools, S. Chanock for critical input and comments, E. Loftfield for assistance with the 25-level smoking adjustment variable, and the participants and staff of the UKB, MGBB, and BBJ. The UKB analyses were conducted using applications 7089 and 21552. The authors thank all of the study participants and their families for contributing to the CUB COVID-19 cohort. The genotyping was made possible by the CUB and its COVID-19 Genomics Workgroup members, including A. Califano, W. Chung, C. K. Garcia, D. B. Goldstein, I. Ionita-Laza, K. Kiryluk, R. Mayeux, S. M. O’Byrne, D. Pendrick, M. P. Reilly, S. Sengupta, P. Sims and A.-C. Uhlemann. The authors acknowledge the COVID-19 Host Genetics Initiative consortium for providing infrastructure for collaboration (the members are listed in the Supplementary Information). P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General Hospital, and grants from the National Heart, Lung, and Blood Institute (R01HL1427, R01HL148565 and R01HL148050). P.N. and B.L.E. are supported by a grant from Fondation Leducq (TNE-18CVD04). S.M.Z. is supported by the NIH National Heart, Lung, and Blood Institute (1F30HL149180-01) and the NIH Medical Scientist Training Program Training Grant (T32GM136651). A.G.B. is supported by a Burroughs Wellcome Fund Career Award for Medical Scientists. G.G. is supported by NIH grant R01 HG006855, NIH grant R01 MH104964, and the Stanley Center for Psychiatric Research. J.P.P. is supported by a John S. LaDue Memorial Fellowship. K.P. is supported by NIH grant 5-T32HL007208-43. P.T.E. is supported by supported grants from the National Institutes of Health (1RO1HL092577, R01HL128914, K24HL105780), the American Heart Association (18SFRN34110082), and by the Foundation Leducq (14CVD01). P.-R.L. is supported by NIH grant DP2 ES030554 and a Burroughs Wellcome Fund Career Award at the Scientific Interfaces. This work was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, extramural grants from the National Heart, Lung, and Blood Institute, and Fondation Leducq. The opinions expressed by the authors are their own and this material should not be interpreted as representing the official viewpoint of the US Department of Health and Human Services, the National Institutes of Health, or the National Cancer Institute. The CUB is supported by the Vagelos College of Physicians and Surgeons as well as the Precision Medicine Resource and Biomedical Informatics Resource of Irving Institute for Clinical and Translational Research, home of the Columbia University’s Clinical and Translational Science Award (CTSA), funded by the National Center for Advancing Translational Sciences, National Institutes of Health, through grant number UL1TR001873.

Author information

Authors and Affiliations

Authors

Consortia

Contributions

S.M.Z., S.-H.L., C.W., M.J.M. and P.N. performed statistical modeling of the UKB, FinnGen and MGB data. C.W. collected and analyzed the CUB data. S.M.Z. carried out the analyses of the GWAS and TWAS. P.-R.L. and G.G. carried out the mCA calls. M.J.M. and P.N. supervised the study. S.M.Z. and S.-H.L. drafted the manuscript. All authors critically reviewed the manuscript.

Corresponding author

Correspondence to Pradeep Natarajan.

Ethics declarations

Competing interests

P.N. reports grants from Amgen during the conduct of the study and grants from Boston Scientific; grants and personal fees from Apple; personal fees from Novartis and Blackstone Life Sciences; and other support from Vertex outside the submitted work. P.T.E. has received grant support from Bayer AG and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia and Novartis, outside of the present work. S.M.Z., S.-H.L., M.J.M., G.G., and P.N. have filed a patent application (serial no. 63/079,74) on the prediction of infection from mCAs. G.G. and S.A.M. have filed a patent application (PCT/WO2019/079493) for the MoChA mCA detection method used in the present study. All other authors have no competing interests.

Additional information

Peer review information Nature Medicine thanks Alexander Mentzer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Michael Basson was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 mCA calls by chromosome.

mCA calls by chromosome in the a) MGBB b) FinnGen, and c) CUB. CN-LOH = copy neutral loss of heterozygosity, CUB = Columbia University Biobank, MGBB = Mass-General Brigham Biobank.

Extended Data Fig. 2 Visualization of the diverse range of expanded autosomal mCAs detected across the genome among individuals with a. incident sepsis and b. incident pneumonia in the UKB.

Each point represents one mCA carried by a case, with the x-axis as the chromosome, y-axis as the mCA size in mega-bases of DNA (Mb), color as the copy change, and size of the point as the cell fraction of that mCA. CNN-LOH = copy number neutral loss of heterozygosity, Mb = megabases of DNA, mCA = mosaic chromosomal alterations.

Extended Data Fig. 3 Suggestive associations (P < 0.05) of expanded autosomal mCAs with specific incident infections by Cox proportional-hazards models.

Analyses are adjusted for age, age2, sex, smoking status, and principal components 1-10 of ancestry. Bonferroni correction was used to determine the level of statistical significance (0.05/20 or P < 0.0025). Overall estimates across studies are generated via fixed effect meta-analysis. Error bars show 95% confidence intervals. mCA = mosaic chromosomal alterations.

Extended Data Fig. 4 Associations of a) expanded ChrY and b) expanded ChrX mCAs with incident infections.

Both panels employ Cox proportional-hazards model adjusting for age, age2, sex, smoking status, and principal components 1–10 of ancestry. Error bars show 95% confidence intervals. Bonferroni correction was used to determine the level of statistical significance for each mCA category (P < 0.005). mCA = mosaic chromosomal alterations.

Extended Data Fig. 5

Suggestive associations (P < 0.05) of mCAs with incident infection-related mortality in Biobank Japan Associations of autosomal mCAs with a) organ-system level infections and b) specific infection categories. c) Association of expanded autosomal mCAs with Sepsis. All panels employ Cox proportional-hazards model adjusting for age, age2, sex, smoking status, and principal components 1–10 of ancestry. Error bars show 95% confidence intervals. Bonferroni correction was used to determine the level of statistical significance. Full results are in Supplementary Table 6. Associations are presented among individuals without any cancer history. mCA = mosaic chromosomal alterations.

Extended Data Fig. 6 Incidence rate of at risk population developing each disease (N = 445,101 UKB participants).

95% confidence intervals were calculated based on normal approximation. mCA = mosaic chromosomal alterations.

Extended Data Fig. 7 Associations of expanded mCAs in the UK Biobank with COVID-19 and incident pneumonia.

Associations of expanded mCAs with a. COVID-19 hospitalization across different adjustment models, and b. different COVID-19 phenotypes in fully adjusted logistic regression models. Adjustment models include (1) an unadjusted model, (2) a sparsely adjusted model which adjusts for age, age2, sex, smoking status, and principal components of ancestry, and (3) a fully adjusted model which additionally adjusts for Townsend deprivation index, BMI, and the following comorbidities: Asthma, COPD, CAD, T2D, any cancer, and HTN. Bonferroni correction was used to determine the level of statistical significance. mCA = mosaic chromosomal alterations, COPD = chronic obstructive pulmonary disease, CAD = coronary artery disease, T2D = type 2 diabetes mellitus. c. Association of expanded mCAs with incident pneumonia stratified by sex, adjusted for age, age2, sex (in the All model only), smoking status, and principal components of ancestry. Error bars show 95% confidence intervals. mCA = mosaic chromosomal alterations.

Extended Data Fig. 8 Correlated associations of 63 independent genome-wide significant variants associated with expanded mCAs between different mCA categories in the UKB.

Bonferroni correction was used to determine the level of statistical significance for the correlation analyses (P < 0.05/6 = 0.0083). Across all panels except for panel (a), the labeled genes represent genes attributed to variants that have P < 0.05 across the mCA categories in both axes. mCA = mosaic chromosomal alterations, rp = Pearson correlation.

Extended Data Fig. 9 Association of a mLOY PRS consisting of 156 previously identified20 independent genome-wide significant variants associated with mLOY, with different expanded mCA categories in UKB Females.

Error bands were derived from binomial proportion standard errors. mCA = mosaic chromosomal alterations, mLOY = mosaic Loss-of-chromosome Y, PRS = polygenic risk score.

Extended Data Fig. 10 Pathway enrichment of TWAS results using the Elsevier Pathways.

a. Top results from pathway enrichment analysis of the TWAS results using the Elsevier Pathways. b. Highlighting the GWAS locus-zoom plots for some of the TWAS genes implicated in the top pathways from panel a. Red boxes highlight the gene(s) with strongest association in the TWAS analyses. GWAS = genome-wide association study, TWAS = transcriptome-wide association study.

Supplementary information

Supplementary Information

Supplementary Figs. 1–19 and Supplementary Tables 1–3, 6–12 and 14.

Reporting Summary

41591_2021_1371_MOESM3_ESM.xlsx

Supplementary Table 4: Infection phenotypic grouping categories across organ systems used in the UK Biobank, MGB Biobank, and Biobank Japan. Supplementary Table 5: Infection phenotypic grouping categories across organ systems used in FinnGen (includes ICD-10, -9, and -8 codes as specified). Supplementary Table 13: 63 independent loci identified in the expanded mCA GWAS. Supplementary Table 15: Transcriptome-wide association using GTExv8-whole blood (n = 670). Supplementary Table 16: Gene set pathway enrichment analysis of the transcriptome-wide analyses (from Supplementary Data 4) using the Elsevier Pathway Collection through EnrichR. Supplementary Table 17: Other phenotype definitions used in the UK Biobank COVID-19 sensitivity analyses. Supplementary Table 18: Other phenotype definitions used in MGB Biobank. Supplementary Table 19: Other phenotype definitions used in FinnGen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zekavat, S.M., Lin, SH., Bick, A.G. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med 27, 1012–1024 (2021). https://doi.org/10.1038/s41591-021-01371-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-021-01371-0

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载